Success Metrics

Clinical Success Rate
89.4%

Based on 42 completed trials

Completion Rate
89%(42/47)
Active Trials
6(10%)
Results Posted
69%(29 trials)
Terminated
5(8%)

Phase Distribution

Ph not_applicable
5
8%
Ph phase_2
16
27%
Ph phase_1
5
8%
Ph phase_3
20
34%
Ph early_phase_1
2
3%
Ph phase_4
11
19%

Phase Distribution

7

Early Stage

16

Mid Stage

31

Late Stage

Phase Distribution59 total trials
Early Phase 1First-in-human
2(3.4%)
Phase 1Safety & dosage
5(8.5%)
Phase 2Efficacy & side effects
16(27.1%)
Phase 3Large-scale testing
20(33.9%)
Phase 4Post-market surveillance
11(18.6%)
N/ANon-phased studies
5(8.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.4%

42 of 51 finished

Non-Completion Rate

17.6%

9 ended early

Currently Active

6

trials recruiting

Total Trials

59

all time

Status Distribution
Active(6)
Completed(42)
Terminated(9)
Other(2)

Detailed Status

Completed42
Recruiting5
Terminated5
Withdrawn4
unknown2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
59
Active
6
Success Rate
89.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.4%)
Phase 15 (8.5%)
Phase 216 (27.1%)
Phase 320 (33.9%)
Phase 411 (18.6%)
N/A5 (8.5%)

Trials by Status

unknown23%
active_not_recruiting12%
recruiting58%
withdrawn47%
completed4271%
terminated58%

Recent Activity

Clinical Trials (59)

Showing 20 of 59 trialsScroll for more
NCT06036004Phase 2

Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus

Recruiting
NCT06615557Phase 3

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Recruiting
NCT05275686Phase 2

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

Recruiting
NCT07240922Phase 4

The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study

Recruiting
NCT06358651Phase 3

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

Active Not Recruiting
NCT05011396Phase 3

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

Terminated
NCT07219849Phase 2

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

Recruiting
NCT04754802Phase 3

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge

Completed
NCT02484716Phase 2

Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)

Completed
NCT03245437Phase 4

Target Engagement and Response to Oxytocin

Completed
NCT05679908Phase 2

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Completed
NCT05485584Phase 2

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19

Completed
NCT00599027Phase 3

An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma

Completed
NCT00378378Phase 3

Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)

Completed
NCT03136263Early Phase 1

Oxytocin and Cognitive Control in Adult ADHD

Completed
NCT04738838Phase 2

Oxytocin on Cold Water Task Performance and Recovery

Completed
NCT04732247Phase 2

Oxytocin for Oxidative Stress and Inflammation

Completed
NCT05159271Not Applicable

Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults

Completed
NCT04666623Phase 2

Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain

Withdrawn
NCT01832402Phase 2

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

Completed

Drug Details

Intervention Type
OTHER
Total Trials
59